AMP® Media and Publications
AMP® Media and Publications
AMP Bespoke Gene Therapy Consortium – Overview of Project
AMP Alzheimer’s Disease – Message from the NIH Director
AMP Rheumatoid Arthritis and Lupus – Message from the NIH Director
AMP Rheumatoid Arthritis and Lupus – Patient Perspectives
AMP Common Metabolic Diseases – Inaugural Meeting Recording
AMP Common Metabolic Diseases – Knowledge Portal Network Update
AMP Type 2 Diabetes – Effector Gene Prediction Symposium Recording
AMP Type 2 Diabetes – Project Conclusion
AMP Press Conference – 2014 Program Launch
AMP Program Publications
Nature Reviews Drug Discovery (February 2019): Massive NIH-industry project opens portals to target validation
NIH Press Release (February 2014): NIH, industry and non-profits join forces to speed validation of disease targets
AMP Project Publication Highlights
Nature Reviews Drug Discovery (September 2022): Accelerating therapeutic discoveries for heart failure: a new public–private partnership
PharmaVoice (June 2022): After losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development
Schizophrenia Bulletin (May 2022): Leading Science with Lived Experience
Letter from the Director (March 2022): NIH awards nine grants to establish the AMP AIM network
Rheumatic Disease Clinics (June 2021): The Power of Systems Biology: Insights on Lupus Nephritis from the Accelerating Medicines Partnership
BioCentury (November 2021): Creating drug master files for AAV vectors
Nature Reviews Drug Discovery (November 2021): ‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases
The Lancet Neurology (October 2020): Developing therapies for Parkinson's disease
Arthritis Care & Research (January 2020): Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.